Departamento de Hematología-Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Departamento de Cirugía Oncológica y Maxilofacial, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Rev Med Chil. 2020 Sep;148(9):1233-1238. doi: 10.4067/S0034-98872020000901233.
About 80% of breast cancer (BC) cases express estrogen receptor (ER), which has been correlated with good prognosis and response to estrogen deprivation Aim: To characterize ER positive advanced BC (ABC) patients treated at our institution assessing the impact of clinical pre-sentation (stage IV, de novo disease at diagnosis versus systemic recurrence) and BC subtype on survival rates.
We evaluated 211 ER+ advanced BC (ABC) patients, treated between 1997 and 2017.
The median overall survival (OS) was 37 months. Median OS for the period 1997/2006 and 2007/2017 were 33 and 42 months, respectively (p = 0.47). Luminal A, ABC stage IV disease at diagnosis displayed better OS rates than Luminal B stage IV tumors (100 and 32 months respectively, p < 0.01).
Clinical presentation (stage IV vs. systemic recurrence) and tumor subtype are key determinants of OS in ABC.
约 80%的乳腺癌（BC）病例表达雌激素受体（ER），这与良好的预后和对雌激素剥夺的反应相关。
通过评估临床表现（IV 期、初诊时疾病已转移与全身性复发）和 BC 亚型对生存率的影响，对在本机构治疗的 ER 阳性晚期 BC（ABC）患者进行特征描述。
我们评估了 211 例 ER+晚期 BC（ABC）患者，他们于 1997 年至 2017 年期间接受治疗。
中位总生存期（OS）为 37 个月。1997/2006 年和 2007/2017 年期间的中位 OS 分别为 33 个月和 42 个月（p = 0.47）。Luminal A 型、初诊时即 IV 期疾病的 ABC 患者的 OS 率优于 Luminal B 型 IV 期肿瘤（分别为 100 个月和 32 个月，p < 0.01）。
临床表现（IV 期与全身性复发）和肿瘤亚型是 ABC 患者 OS 的关键决定因素。
